Andrew Cittadine - 02 Feb 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-Fact
Issuer symbol
MNPR
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 18:29:56 UTC
Previous filing
02 Jul 2021
Next filing
01 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +85,000 $0.000000 85,000 02 Feb 2022 Common Stock 85,000 $2.80 Direct F1
transaction MNPR Restricted Stock Units Award $0 +65,000 $0.000000 65,000 02 Feb 2022 Common Stock 65,000 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
F2 RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)